The gut–brain axis in early Parkinson’s disease: from prodrome to prevention
Open accessThe DOI matches its Crossref record; 275 of the 275 references it cites were found in a registry or an index; 107 of the 188 sources its claims cite were checked for support.
Abstract
Parkinson's disease is the second most common neurodegenerative disorder and fastest growing neurological condition worldwide, yet its etiology and progression remain poorly understood. This disorder is characterized pathologically by the prion-like spread of misfolded neuronal alpha-synuclein proteins in specific brain regions leading to Lewy body formation, neurodegeneration, and progressive neurological impairment. It is unclear what triggers Parkinson's and where α-synuclein protein aggregation begins, although proposed induction sites include the olfactory bulb and dorsal motor nucleus of the vagus nerve. Within the last 20 years, there has been increasing evidence that Parkinson's could be triggered by early microbiome changes and α-synuclein accumulation in the gastrointestinal system. Gut microbiota dysbiosis that alters gastrointestinal motility, permeability, and inflammation could enable prion-like spread of α-synuclein from the gut-to-brain via the enteric nervous system. Individuals with isolated rapid eye movement sleep behavior disorder have a high likelihood of developing Parkinson's and might represent a prodromal 'gut-first' subtype of the condition. The gut-first model of Parkinson's offers novel gut-based therapeutic avenues, such as anti-, pre-, and pro-biotic preparations and fecal microbiota transplants. Crucially, gut-based interventions offer an avenue to treat Parkinson's at early prodromal stages with the aim of mitigating evolution to clinically recognizable Parkinson's disease characterized by motor impairment.
Overview
CoChat Summary
## TL;DR
This is a narrative review arguing that Parkinson’s disease may begin in the gut in at least a subset of patients, especially those with prodromal rapid eye movement sleep behavior disorder (RBD), and that gut microbiome changes could help identify and treat disease earlier. The authors conclude that the gut-first model is promising but still largely speculative and needs prospective longitudinal and interventional studies.
## Key findings
- Prodromal Parkinson’s disease is described as predominantly non-motor; the paper notes early constipation and gastrointestinal complaints in 80% of PD patients and states that RBD to overt α-synucleinopathies converts at 6.3% per year, with 73.5% converting after 12-year follow up.
- The review says evidence is mixed for peripheral α-synuclein before brain involvement: some post-mortem and immunohistochemical studies found α-synuclein in the esophagus, stomach, small intestine, and enteric nervous system up to 20 years before diagnosis, but a large Arizona Parkinson’s consortium study did not find cases with enteric nervous system α-synuclein without central nervous system involvement.
- It reports that gut microbiota dysbiosis is seen in prodromal PD, but study results are heterogeneous; sample sizes range from 38 in individual studies to 1269 in meta-analyses, and the authors say many studies are underpowered and confounded by geography, diet, smoking, medications, and other factors.
- For treatment, the paper highlights gut-based interventions: it says 4 RCTs of fecal microbiota transplant (FMT) have available evidence, 3 reported changes in global or motor function, and 2 reported significant improvement in UPDRS scores at 12 weeks and 12 months, respectively.
## Methods
- Narrative review synthesizing epidemiological, post-mortem, imaging, animal, and interventional studies on the gut–brain axis in early Parkinson’s disease.
- Focuses on prodromal PD, especially RBD-positive and body-first phenotypes, and on gut microbiome findings from 16S rRNA studies, shotgun metagenomics, and related biomarker work.
- No original dataset or primary statistical analysis is presented in the paper itself; it reviews and interprets prior studies.
## Limitations
- The paper explicitly states that the current evidence for gut-first Parkinson’s disease remains “largely speculative” and that there are conflicting reports across microbiome, histopathology, and epidemiological studies.
- It notes several limitations in the literature it reviews: small and heterogeneous samples, inadequate control of covariates, lack of a priori power calculations, limited species/strain resolution in 16S methods, and inconsistent bioinformatic/normalization approaches.
- The text makes evident that this is a narrative synthesis rather than a systematic review or meta-analysis; therefore, its conclusions depend on the quality and selection of prior studies (this is inferred from the text).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
64 Valid · 9 Not valid · 31 Not checked · 42 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“At the molecular level, in vitro data indicate that SCFAs might contribute to α-synuclein pathogenesis.”
§ The gut–brain axis in early Parkinson’s disease: from prodrome to prevention > Gut microbiota dysbiosis is seen in prodromal PD
What the sources say
- Not checked — no full text of the sourcecites [121] Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer R (2008) Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. https://doi.org/10.1111/j.1365-2036.2007.03562.x source
- Could not verifycites [122] Biagi E, Nylund L, Candela M, Ostan R, Bucci L, Pini E, Nikkïla J, Monti D, Satokari R, Franceschi C, Brigidi P, De Vos W (2010) Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS ONE. https://doi.org/10.1371/journal.pone.0010667 sourceExperimental — accuracy not yet measured
The Discussion describes butyrate as a short-chain fatty acid and reports changes in butyrate-producing gut bacteria in centenarians. Searches for α-synuclein, Parkinson’s disease, and in vitro SCFA effects found no passage connecting SCFAs to α-synuclein pathogenesis. (LLM, conf=0.76)
- Not checked — no full text of the sourcecites [123] Qu Y, An K, Wang D, Yu H, Li J, Min Z, Xiong Y, Xue Z, Mao Z (2025) Short-chain fatty acid aggregates alpha-synuclein accumulation and neuroinflammation via GPR43-NLRP3 signaling pathway in a model Parkinson’s disease. Mol Neurobiol. https://doi.org/10.1007/s12035-025-04726-7 source
- Disputedcites [124] Liu J, Chen Q, Su R (2024) Interplay of human gastrointestinal microbiota metabolites: short-chain fatty acids and their correlation with Parkinson’s disease. Medicine (Baltimore). https://doi.org/10.1097/MD.0000000000037960 sourceExperimental — accuracy not yet measured
Section 4.3 reports that SCFAs downregulate α-synuclein aggregation and that sodium butyrate promotes its degradation in cell-based and rotenone-induced models. Those findings point away from the claimed contribution to α-synuclein pathogenesis, rather than supporting it. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In this study, only 3% of the treatment group were reported to show a change from dysbiotic to non-dysbiotic status, compared to 33% in the placebo arm, suggesting that the FMT treatment failed to produce a significant change in the gut microbiome.”
§ The gut–brain axis in early Parkinson’s disease: from prodrome to prevention > A gut-first model of PD opens new avenues for treatment
What the sources say
- Disputedcites [206] Scheperjans F, Levo R, Bosch B, Lääperi M, Pereira PAB, Smolander O, Aho VTE, Vetkas N, Toivio L, Kainulainen V, Fedorova TD, Lahtinen P, Ortiz R, Kaasinen V, Satokari R, Arkkila P (2024) Fecal microbiota transplantation for treatment of Parkinson disease: a randomized clinical trial. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2024.2305 sourceExperimental — accuracy not yet measured
The cited proportions are accurate — Results (GMB section) report dysbiosis conversion to nondysbiotic falling from 7/29 (24%) at 1 month to 1/29 (3%) at 12 months in the FMT group versus 2/15 (13%) rising to 5/15 (33%) at 12 months in placebo. However, the inference drawn from them is contrary to the source: the same Results section states 'Microbiota changes were more pronounced after FMT but differed by donor,' with beta diversity (Bray-Curtis) increasing significantly more in the FMT group at strain and species levels and more abundant taxonomic shifts at 1 month, and the Discussion adds that 'donor FMT achieved a sustained GMB change close to what is observed between individuals' (species-level sustained dissimilarity 0.36-0.43 FMT vs 0.26-0.32 placebo). What the trial found futile was clinical/biomarker benefit and sustained dysbiosis reversal, not a significant microbiome change. (LLM, conf=0.80)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [207] Cheng Y, Tan G, Zhu Q, Wang C, Ruan G, Ying S, Qie J, Hu X, Xiao Z, Xu F, Chen L, Chen M, Pei Y, Zhang H, Tian Y, Chen D, Liu X, Huang H, Wei Y (2023) Efficacy of fecal microbiota transplantation in patients with Parkinson’s disease: clinical trial results from a randomized, placebo-controlled design. Gut Microbes. https://doi.org/10.1080/19490976.2023.2284247 sourceExperimental — accuracy not yet measured
The Results section on metagenomic sequencing (page unavailable) says gut-microbiota alpha and beta diversity did not change significantly after FMT or placebo, supporting the narrower point about diversity. It does not report the cited 3% versus 33% dysbiosis-status figures, and it reports differences in microbial species and community networks among FMT responders, so the broader claim of no significant microbiome change is overstated. (LLM, conf=0.86)
- Disputedcites [208] DuPont HL, Suescun J, Jiang Z, Brown EL, Essigmann HT, Alexander AS, DuPont AW, Iqbal T, Utay NS, Newmark M, Schiess MC (2023) Fecal microbiota transplantation in Parkinson’s disease-A randomized repeat-dose, placebo-controlled clinical pilot study. Front Neurol. https://doi.org/10.3389/fneur.2023.1104759 sourceExperimental — accuracy not yet measured
The Results (Primary endpoints; page unavailable) report significant differences between the FMT and placebo groups in microbiome beta diversity at 6 weeks (p = 0.008) and 13 weeks (p = 0.0008), as well as significant differences in bacterial families at 13 weeks. The Discussion likewise says beta diversity increased significantly in the FMT group. The copy does not report the claimed 3% versus 33% change from dysbiotic to non-dysbiotic status. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Could not verifycites [209] Bruggeman A, Vandendriessche C, Hamerlinck H, De Looze D, Tate DJ, Vuylsteke M, De Commer L, Devolder L, Raes J, Verhasselt B, Laukens D, Vandenbroucke RE, Santens P (2024) Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson’s disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2024.102563 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that sequential microbiome analysis before and after FMT is a future step, rather than reporting whether this trial found a significant microbiome change. A search for dysbiotic-to-non-dysbiotic status and the cited 3% and 33% figures found no matching results in our copy. (LLM, conf=0.76)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recent analyses reveal that early constipation and gastrointestinal complaints are seen in 80% of PD patients [23, 24].”
§ The gut–brain axis in early Parkinson’s disease: from prodrome to prevention > Prodromal PD is a non-motor phenomenon
What the sources say
- Partly supportedcites [23] Scheperjans F, Pekkonen E, Kaakkola S, Auvinen P (2015) Linking smoking, coffee, urate, and Parkinson’s disease: A role for gut microbiota? J Parkinsons Dis. https://doi.org/10.3233/JPD-150557 sourceExperimental — accuracy not yet measured
In “The Gut and Its Microbiota in PD” (page not provided), the paper says gastrointestinal dysfunction, particularly constipation, affects up to 80% of PD patients and that related changes can occur in the earliest stages. It does not say that 80% of patients have these complaints early in the disease, and “up to 80%” is an upper bound rather than a fixed rate. (LLM, conf=0.86)
- Supportedcites [24] Jia X, Chen Q, Zhang Y, Asakawa T (2023) Multidirectional associations between the gut microbiota and Parkinson’s disease, updated information from the perspectives of humoral pathway, cellular immune pathway and neuronal pathway. Front Cell Infect Microbiol. https://doi.org/10.3389/fcimb.2023.1296713 source
The Introduction reports GI dysfunction in 80% of early PD patients. Section 2.1 identifies constipation as one of the gastrointestinal symptoms experienced by PD patients. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“First, non-motor symptoms such as constipation and bloating are among the earliest seen in prodromal PD [10, 11].”
§ The gut–brain axis in early Parkinson’s disease: from prodrome to prevention > Abstract
What the sources say
- Partly supportedcites [10] Scott GD, Lim MM, Drake MG, Woltjer R, Quinn JF (2021) Onset of skin, gut, and genitourinary prodromal parkinson’s disease: a study of 1.5 million veterans. Mov Disord. https://doi.org/10.1002/mds.28636 sourceExperimental — accuracy not yet measured
The Results section, “Estimated Onset Times for Gastrointestinal, Genitourinary, and Skin Disorders” (page unavailable), places constipation early in prodromal PD, with an estimated onset 17.3 years before diagnosis. It does not identify bloating, and it places constipation later than the earliest-onset disorders. (LLM, conf=0.86)
- Partly supportedcites [11] Adams-Carr KL, Bestwick JP, Shribman S, Lees A, Schrag A, Noyce AJ (2016) Constipation preceding Parkinson’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2015-311680 sourceExperimental — accuracy not yet measured
The Introduction (p.1) states that 'Constipation, a consequence of autonomic dysfunction, is one of the most studied of the prodromal symptoms of PD', and the Abstract/Discussion conclude that 'constipation can predate Parkinson's diagnosis by over a decade' with a persistent 2.13-fold risk >10 years before diagnosis — supporting constipation as an early non-motor prodromal feature. However, our copy nowhere mentions bloating (searched: bloating, gastrointestinal/autonomic non-motor symptoms), so that element of the claim is not attributed to this paper. Note also that the paper's own ranking ('second most common non-motor symptom after anosmia') is a prevalence statement credited to Chen et al. (ref 4), not a claim about ordering of onset. (LLM, conf=0.78)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A leaky gut barrier has been linked to PD pathogenesis involving local flux of bacterial toxins, microbes, and potentially molecules like α-synuclein across the gastrointestinal epithelium [29–31]”
§ The gut–brain axis in early Parkinson’s disease: from prodrome to prevention > Prodromal PD is a non-motor phenomenon
What the sources say
- Not checked — no full text of the sourcecites [29] Schwiertz A, Spiegel J, Dillmann U, Grundmann D, Bürmann J, Faßbender K, Schäfer K, Unger MM (2018) Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson’s disease. Parkinsonism Relat Disord. https://doi.org/10.1016/j.parkreldis.2018.02.022 source
- Partly supportedcites [30] Kelly LP, Carvey PM, Keshavarzian A, Shannon KM, Shaikh M, Bakay RAE, Kordower JH (2014) Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson’s disease. Mov Disord. https://doi.org/10.1002/mds.25736 sourceExperimental — accuracy not yet measured
The Abstract hypothesizes that a leaky gut permits bacterial endotoxin (LPS) to pass from the intestinal lumen into enteric tissues, and the Discussion links permeability dysfunction to inflammation and neuronal damage in PD. The paper does not establish that whole microbes or α-synuclein cross the gastrointestinal epithelium; it describes α-synuclein expression in enteric neurons instead. Page numbers are unavailable in our copy. (LLM, conf=0.87)
- Partly supportedcites [31] Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, Estes JD, Dodiya HB, Keshavarzian A (2011) Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson’s disease. PLoS ONE. https://doi.org/10.1371/journal.pone.0028032 sourceExperimental — accuracy not yet measured
The Introduction and Discussion link increased intestinal permeability in PD to the passage of bacteria and endotoxins across the gut barrier, and report a correlation with intestinal α-synuclein staining. They do not suggest that α-synuclein itself crosses the gastrointestinal epithelium; instead, they propose that local inflammatory and oxidative injury may contribute to its accumulation in enteric neurons. The Discussion also cautions that this observational study cannot establish a causal role in PD pathogenesis. (LLM, conf=0.88)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
70 more claims · 37 with their cited sources checked
Create a free account to see all 146 claims and to verify the 21 references still open.
- It may state two separate claims as one. 58
- Probably not a substantial claim. 19
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Some studies have found no difference in SCFA levels between individuals with RBD compared to controls [128, 129], and one study reported no significant association between the non-motor features of prodromal PD and microbiome changes [130].”
Cited work 10.1002/ana.25788 · retracted 2021-07-14 · notice 10.1002/ana.26151 · this paper published 2025-05-21
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Several other RCTs have consistently shown probiotics can improve constipation in PD patients [166–169].”
Cited work 10.1016/j.clnu.2018.05.018 · retracted 2025-09-26 · notice 10.1016/j.clnu.2025.08.012 · this paper published 2025-05-21
Citations
Cites
2 retracted
Tamtaji, O. R., Taghizadeh, M., Daneshvar Kakhaki, R., Kouchaki, E., Bahmani, F., Borzabadi, S., Oryan, S., Mafi, A., & Asemi, Z. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.05.018 · Cited by 398 · cited 1×
“Several other RCTs have consistently shown probiotics can improve constipation in PD patients [166–169].”
RetractedRetracted: Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease
Heinzel, S., Aho, V. T. E., Suenkel, U., von Thaler, A., Schulte, C., Deuschle, C., Paulin, L., Hantunen, S., Brockmann, K., Eschweiler, G. W., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25788 · Cited by 95 · cited 1×
“Some studies have found no difference in SCFA levels between individuals with RBD compared to controls [128, 129], and one study reported no significant association between the non-motor features of prodromal PD and microbiome changes [130].”
RetractedA human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624 · cited 1×
“The number of genes encoded in the gut metagenome is approximately 150 times larger than that of the human genome [89].”
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“In this model outlined by Braak et al., early α-synuclein induction sites are found in the brain, including the dorsal motor nucleus or the vagus and the olfactory bulb, with spread”
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 1×
“Fecal microbiota transplants (FMTs) could be used as a safe and efficacious method to manipulate the gut micro-biome and treat PD and is licensed for use in many countries for treating Clostridium difficile infections [200, 201].”
The Human Intestinal Microbiome in Health and Disease
Lynch, S. V., & Pedersen, O. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1600266 · Cited by 3,637 · cited 1×
“Gut dysbiosis involves an altered composition of the organisms found in the gut microbiome, such as a loss of normal healthy commensals, an overgrowth of pathobionts which have the potential to cause pathology, or a decrease in microbial species diversity [93, 94].”
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622 · cited 1×
“When these mice were either colonized with feces from wild-type mice or orally fed bacterial metabolites like short chain fatty acids (SCFAs) without colonization, they developed a PD-like phenotype [92].”
Desai, M. S., Seekatz, A. M., Koropatkin, N. M., Kamada, N., Hickey, C. A., Wolter, M., Pudlo, N. A., Kitamoto, S., Terrapon, N., Muller, A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.10.043 · Cited by 2,805 · cited 1×
“Akkermansia is a mucin-degrading bacterium and investigations on mice have found that Akkermansia can deplete the intestinal mucosal layer, decrease the number of goblet cells, produce drier stools, slow colonic transit, and impair intestinal barrier function [106–108].”
Research works printed but not linked: 1
- Huang B, Chau SW, Liu Y, Chan JW, Wang J, Ma SL, Zhang J, Chan PK, Yeoh YK, Chen Z (2023) Gut microbiome dysbiosis across early Parkinson’s disease, REM sleep behavior disorder and their first-degree relatives. Nature Commun 14(1):2501 · DOI · Paper page
Cited by
Neurodegeneration as Ecosystem Failure: A New Paradigm for Prevention and Treatment
Velikic, G. S., Šupić, G., Marić, D., Puletić, M., Kos, M. O., Vojvodić, D., & Maric, D. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211207 · Cited by 14
“Additional multicentric efforts examining gut–brain communication [10,120,121], cardiac denervation patterns, and peripheral α -syn pathology [122–125] have established that organ–brain axis dysfunction is not conjectural but represents a well-documented and systematically studied aspect of…”
Faecal microbiota transplant for Parkinson’s disease: promises and future directions
Tan, E. K., Wang, J. D. J., Pettersson, S., Wang, Q., Takahashi, R., Poewe, W. H., Jankovic, J. J., & Rascol, O. (2025) · Brain · doi:10.1093/brain/awaf419 · Cited by 12
Miquel-Rio, L., Jericó-Escolar, J., Yanes-Castilla, C., Sarriés-Serrano, U., Paz, V., Callado, L. F., Meana, J. J., & Bortolozzi, A. A. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03608-y · Cited by 12
Aliuş, C., Breazu, A., Panţu, C., Toader, C., Șerban, M., Covache-Busuioc, R.-A., Munteanu, O., & Dumitru, A. V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262210959 · Cited by 12
García‐Yagüe, Á. J., Esteras, N., Dinkova‐Kostova, A. T., Rojo, A. I., Shiels, P. G., Dinnyés, A., Tamas, V., van Goor, H., & Lastres‐Becker, I. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.01.023 · Cited by 13
Metadata
- Authors
- Oliver, P. J., Civitelli, L., & Hu, M. T.
- Affiliations
- University of Oxford (GB)
- John Radcliffe Hospital (GB)
- Corresponding author
- Hu, Michele T.
- Venue
- Journal of Neurology
- Published
- 2025-05-21
- Volume
- 272
- Issue
- 6
- Pages
- 413-413
- ISSN
- 0012-1037 (ISSN-L)
- 0340-5354
- 1432-1459
- PMC
- PMC12092510
- OpenAlex
- W4410514566
- Cited by
- 42
- References
- 272
- Citations by year
- 2026: 32 · 2025: 10
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Neurology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Parkinson's disease, gut-brain axis, gut dysbiosis, alpha-synuclein aggregation, prion-like spread, prodromal Parkinson's disease, REM sleep behavior disorder, enteric nervous system, probiotics, prebiotics, fecal microbiota transplantation, Lewy bodies, neurodegeneration, Parkinson's disease prevention
- MeSH terms
- Gastrointestinal Microbiome, Brain-Gut Axis, Animals, Brain, Humans, Parkinson Disease, alpha-Synuclein, Prodromal Symptoms, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The gut–brain axis in early Parkinson’s disease: from prodrome to prevention. https://app.cochat.ai/papers/10.1007/s00415-025-13138-5
- The paper
- Oliver, P. J., Civitelli, L., & Hu, M. T. (2025). The gut–brain axis in early Parkinson’s disease: from prodrome to prevention. Journal of Neurology. https://doi.org/10.1007/s00415-025-13138-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.